These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38014499)

  • 21. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice.
    Clavio M; Crisà E; Miglino M; Guolo F; Ceccarelli M; Salvi F; Allione B; Ferrero D; Balleari E; Finelli C; Poloni A; Selleri C; Danise P; Cilloni D; Di Tucci AA; Cametti G; Freilone R; Fanin R; Bigazzi C; Zambello R; Crugnola M; Oliva EN; Centurioni R; Alesiani F; Catarini M; Castelli A; Abbadessa A; Capalbo SF; Musto P; Angelucci E; Santini V
    Cancer; 2021 Jun; 127(12):2015-2024. PubMed ID: 33739457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
    Adès L; Itzykson R; Fenaux P
    Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes.
    van den Bosch J; Lübbert M; Verhoef G; Wijermans PW
    Leuk Res; 2004 Aug; 28(8):785-90. PubMed ID: 15203276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low serum vitamin D levels are associated with shorter survival after first-line azacitidine treatment in patients with myelodysplastic syndrome and secondary oligoblastic acute myeloid leukemia.
    Radujkovic A; Schnitzler P; Ho AD; Dreger P; Luft T
    Clin Nutr; 2017 Apr; 36(2):542-551. PubMed ID: 26899917
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.
    Zeidan AM; Lee JW; Prebet T; Greenberg P; Sun Z; Juckett M; Smith MR; Paietta E; Gabrilove J; Erba HP; Katterling RP; Tallman MS; Gore SD
    Br J Haematol; 2014 Oct; 167(1):62-8. PubMed ID: 24995683
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Platelet Count Doubling after One Course of Demethylated Drug Therapeutic Predicts the Treatment Response and Efficacy of Patients with Myelodysplastic Syndrome].
    Hui H; Yu HY; Li DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):184-189. PubMed ID: 38387919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Five-day versus 7-day treatment regimen with azacitidine in lower risk myelodysplastic syndrome: A phase 2, multicenter, randomized trial.
    Park S; Park SY; Lee JH; Choi EJ; Lee KH; Yoon SS; Hong J; Shin DY; Kim YJ
    Cancer; 2022 Dec; 128(23):4095-4108. PubMed ID: 36208097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
    Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
    Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Upregulated hypoxia inducible factor 1α signaling pathway in high risk myelodysplastic syndrome and acute myeloid leukemia patients is associated with better response to 5-azacytidine-data from the Hellenic myelodysplastic syndrome study group.
    Mpakou V; Spathis A; Bouchla A; Tsakiraki Z; Kontsioti F; Papageorgiou S; Bazani E; Gkontopoulos K; Thomopoulos T; Glezou I; Galanopoulos A; Symeonidis A; Diamantopoulos PT; Viniou NA; Kontandreopoulou CN; Zafeiropoulou K; Kotsianidis I; Lamprianidou E; Foukas P; Mpamias A; Pappa V
    Hematol Oncol; 2021 Apr; 39(2):231-242. PubMed ID: 33332639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
    Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome.
    Falconi G; Fabiani E; Criscuolo M; Fianchi L; Finelli C; Cerqui E; Pelosi E; Screnci M; Gurnari C; Zangrilli I; Postorino M; Laurenti L; Piciocchi A; Testa U; Lo-Coco F; Voso MT
    Leuk Res; 2019 Sep; 84():106191. PubMed ID: 31386932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).
    DeZern AE; Zeidan AM; Barnard J; Hand W; Al Ali N; Brown F; Zimmerman C; Roboz GJ; Garcia-Manero G; Steensma DP; Komrokji RS; Sekeres MA;
    Leuk Lymphoma; 2017 Jun; 58(6):1325-1331. PubMed ID: 27774847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.
    Prébet T; Gore SD; Esterni B; Gardin C; Itzykson R; Thepot S; Dreyfus F; Rauzy OB; Recher C; Adès L; Quesnel B; Beach CL; Fenaux P; Vey N
    J Clin Oncol; 2011 Aug; 29(24):3322-7. PubMed ID: 21788559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic value of monosomal karyotype (MK) in higher-risk patients with myelodysplastic syndromes treated with 5-Azacitidine: A retrospective analysis of the Hellenic (Greek) Myelodysplastic syndromes Study Group.
    Papageorgiou SG; Vasilatou D; Kontos CK; Kotsianidis I; Symeonidis A; Galanopoulos AG; Hatzimichael E; Megalakaki A; Poulakidas E; Diamantopoulos P; Vassilakopoulos TP; Zikos P; Papadaki H; Mparmparousi D; Bouronikou E; Panayiotidis P; Viniou NA; Pappa V
    Am J Hematol; 2018 Jul; 93(7):895-901. PubMed ID: 29659040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship between Low Pretreatment Geriatric Nutritional Risk Index and Poor Tolerability of Azacitidine in Patients with Myelodysplastic Syndromes.
    Kanehira D; Koinuma M; Kato T; Abe T; Sagara A; Sato F; Yumoto T
    Ann Nutr Metab; 2020; 76(6):405-412. PubMed ID: 33662960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
    García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
    Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A systematic review and meta
    Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
    Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
    van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
    Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study.
    Prebet T; Sun Z; Ketterling RP; Zeidan A; Greenberg P; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Figueroa M; Gabrilove J; Erba HP; Tallman MS; Litzow M; Gore SD;
    Br J Haematol; 2016 Feb; 172(3):384-91. PubMed ID: 26577691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Biomarkers predicting the efficacy of DNA hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia: TET enzymes].
    Chiba S
    Rinsho Ketsueki; 2018; 59(5):594-601. PubMed ID: 29877251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.